Anabolic Therapy in Postmenopausal Osteoporosis

Study Overview
=================
Brief Summary
-----------------
In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

Official Title
-----------------
Anabolic Therapy in Postmenopausal Osteoporosis

Conditions
-----------------
Postmenopausal Osteoporosis

Intervention / Treatment
-----------------
* Drug: Romosozumab
* Drug: Denosumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal women at high risk of fracture Exclusion Criteria: Prior therapy exclusions current use or use in the past 12 months of oral bisphosphonates or denosumab current use or use within the past 3 months of estrogens, SERMs, or calcitonin. use of oral or parenteral glucocorticoids for more than 14 days within the past 6 months any current or previous use of romosozumab or strontium current use or use within the past 3 years of teriparatide, abaloparatide, or any parenteral bisphosphonate. Other exclusions Confirmed serum alkaline greater than 2 times the upper normal limit. Stage 4 or 5 chronic kidney disease (GFR less than 30) Hypercalcemia (Ca greater than 10.5 mg/dL) Hypocalcemia (Ca less than 8.8 mg/dL) Elevated blood PTH (intact PTH greater than 77 pg/mL) Serum 25-OH vitamin D less than 20 ng/mL HCT less than 32%. History of malignancy (except basal cell carcinoma). Significant pulmonary disease History of myocardial infarction or stroke within the preceding year. History of unstable angina or transient ischemic attack in the past year. Current atrial fibrillation. Any health condition that, in the opinion of the study physician, significantly increases the risk of cardiovascular events. Major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures. Excessive alcohol use or substance abuse that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures. Uncontrolled eczema Congenital or acquired bone disease other than osteoporosis. Known sensitivity to denosumab or any of its excipients. Known sensitivity to romosozumab or any of its excipients. History of osteonecrosis of the jaw, extensive dental work involving extraction or dental implants in the past 3 months, or extensive dental work planned in the upcoming 12 months.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Romosozumab and denosumab<br> | Drug: Romosozumab<br>* Monthly romosozumab<br>Drug: Denosumab<br>* Every 6 months denosumab<br>|
| Active Comparator: Romosozumab<br> | Drug: Romosozumab<br>* Monthly romosozumab<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total hip areal bone mineral density | Change in total hip bone density between month 0 and month 12 | Month 0 to 12 |